1. Background
3. Methods
3.1. Study Population
3.2. Sample Collection
3.3. Serologic Tests Using Enzyme-linked Immunosorbent Assays
3.4. DNA/RNA Isolation
3.5. Detection of HCV-RNA and HBV-DNA Using Real-Time Polymerase Chain Reaction
3.6. HCV Genotyping by Restriction Fragment Length Polymorphism and Sequencing
The phylogenetic tree conducted based on the sequences of a conserved region of the nonstructural protein 5B gene of the hepatitis C virus obtained from the peripheral blood mononuclear cell sample of 1 working child with occult hepatitis C virus infection, as well as those corresponding to various hepatitis C virus reference sequences retrieved from the GenBank database. The bootstrap values equal to or greater than 70 obtained after 1000 replicates are illustrated in the nodes of the tree.
3.7. Statistical Analysis
4. Results
| Parameters | Male | Female | Total | P-Value |
|---|---|---|---|---|
| Demographic parameters | ||||
| No. of patients | 229 (61.9) | 141 (38.1) | 370 (100) | - |
| Nationality | 0.114 b | |||
| Iranian | 45 (19.7) | 20 (14.2) | 65 (17.6) | |
| Afghan | 184 (80.3) | 121 (85.8) | 305 (82.4) | |
| Age (y) | 10.4 ± 2.2 (7 - 15) | 9.5 ± 1.7 (6 - 13) | 10.1 ± 2.1 (6 - 15) | < 0.001 c, d |
| Laboratory data | ||||
| HCV Ab | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | - |
| HCV RNA in plasma | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | - |
| HCV RNA in PBMC1 | 1 (0.4) | 0.0 (0.0) | 1 (0.3) | 0.619 b |
| HBsAg | 2 (0.9) | 0.0 (0.0) | 2 (0.5) | 0.382 b |
| HBsAb | 80 (34.9) | 69 (48.9) | 149 (40.3) | 0.005 b, c |
| HBcAb | 2 (0.9) | 1 (0.7) | 3 (0.8) | 0.675 b |
| HBV DNA in plasma | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | - |
| HBV DNA in PBMC3 | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | - |
| White blood cells | 6800 ± 1607 (3700 - 11000) | 6300 ± 1436 (4200 - 10000) | 6600 ± 1564 (3700 - 11000) | 0.002 c, d |
| Hemoglobin (g/dL) | 13.2 ± 0.9 (11 - 15) | 12.4 ± 1.1 (9.8 - 14) | 12.9 ± 1.1 (9.8 - 15) | < 0.001 c, d |
| Hemoglobin categorized | < 0.001 b, c | |||
| < 11.5 g/dL | 12.0 (5.2) | 34.0 (24.1) | 46 (12.4) | |
| ≥ 11.6 g/dL | 217.0 (94.8) | 107.0 (75.9) | 324 (87.6) | |
| Iron (mg/dL) | 73.8 ± 22.6 (32 - 120) | 74.7 ± 20.6 (18 - 118) | 74.1 ± 21.8 (18 - 120) | 0.735 e |
| Calcium (mg/dL) | 10.1 ± 0.6 (7.4 - 10.8) | 10.2 ± 0.2 (9.6 - 10.6) | 10.1 ± 0.5 (7.4 - 10.8) | 0.815 d |
| Calcium categorized | 0.008 b, c | |||
| < 8.8 mg/dL | 11.0 (4.8) | 0.0 (0.0) | 11 (3.0) | |
| ≥ 8.9 mg/dL | 218.0 (95.2) | 141.0 (100) | 359 (97.0) | |
| Phosphorus (mg/dL) | 4.8 ± 0.5 (3.6 - 5.9) | 4.9 ± 0.5 (3.3 - 5.8) | 4.9 ± 0.5 (3.3 - 5.9) | 0.114 e |
| Fasting blood sugar (mg/dL) | 84.7 ± 9.3 (65 - 115) | 87.3 ± 8.2 (68 - 107) | 85.7 ± 9.0 (65 - 115) | 0.006 c, e |
| Urea (mg/dL) | 22.6 ± 4.7 (13 - 35) | 22.1 ± 5.9 (13 - 38) | 22.4 ± 5.2 (13 - 38) | 0.150 d |
| Creatinine (mg/dL) | 0.6 ± 0.08 (0.5 - 0.9) | 0.5 ± 0.05 (0.5 - 0.7) | 0.6 ± 0.09 (0.5 - 0.9) | < 0.001 c, d |
| Uric acid (mg/dL) | 3.8 ± 1.1 (1.9 - 6.6) | 3.2 ± 0.63 (1.9 - 4.6) | 3.6 ± 0.99 (1.9 - 6.6) | < 0.001 c, d |
| Cholesterol (mg/dL) | 149 ± 25.7 (104 - 216) | 162 ± 20.9 (112 - 207) | 154.1 ± 24.8 (104 - 216) | < 0.001 c, e |
| Triglyceride (mg/dL) | 86.3± 43.5 (25 - 210) | 77.8 ± 41.0 (29 - 191) | 83.0 ± 42.5 (25 - 210) | 0.023 c, d |
| Level of education, grade | 0.002 c, f | |||
| First | 35 (15.3) | 22 (15.6) | 57 (15.4) | |
| Second | 45 (19.7) | 45 (31.9) | 90 (24.3) | |
| Third | 36 (15.7) | 33 (23.4) | 69 (18.6) | |
| Fourth | 35 (15.3) | 17 (12.1) | 52 (14.1) | |
| Fifth | 48 (21.0) | 11 (7.8) | 59 (15.9) | |
| Sixth | 30 (13.1) | 13 (9.2) | 43 (11.6) |
Abbreviation: PBMCs, peripheral blood mononuclear cells.
a All the continuous data were represented by the mean ± SD (for normally distributed data) or by the median and interquartile (for non-normally distributed data). Categorical data were presented by the No. (%).
b Fisher exact test
c Statistically significant
d Mann - Whitney U test
et-test
f Chi-square
| Parameters | Iranian Children | Afghan Children | Total | P-Value |
|---|---|---|---|---|
| Demographic parameters | ||||
| No. of patients | 65 (17.6) | 305 (82.4) | 370 (100) | - |
| Sex | 0.114 b | |||
| Male | 45 (69.2) | 184 (60.3) | 229 (61.9) | |
| Female | 20 (30.8) | 121 (39.7) | 141 (38.1) | |
| Age (y) | 9.1 ± 2.0 (6 - 13) | 10.3 ± 2.1 (6 - 15) | 10.1 ± 2.1 (6 - 15) | < 0.001 c, d |
| Laboratory data | ||||
| HCV Ab | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| HCV RNA in plasma | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| HCV RNA in PBMC1 | 0 (0.0) | 1 (0.3) | 1 (0.3) | 0.824 b |
| HBsAg | 0 (0.0) | 2 (0.7) | 2 (0.5) | 0.321 b |
| HBsAb | 27 (41.5) | 122 (40.0) | 149 (40.3) | 0.462 b |
| HBcAb | 1 (1.5) | 2 (0.7) | 3 (0.8) | 0.441 b |
| HBV DNA in plasma | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| HBV DNA in PBMC3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| White blood cells | 6756 ± 1796 (3700 - 10000) | 6603 ± 1512 (4200 - 11000) | 6600 ± 1564 (3700 - 11000) | 0.002 c, d |
| Hemoglobin (g/dL) | 13.0 ± 1.0 (11 - 14.7) | 12.9 ± 1.1 (9.8 - 15) | 12.9 ± 1.1 (9.8 - 15) | < 0.001 c, d |
| Hemoglobin categorized | 1.000 b | |||
| < 11.5 g/dL | 57 (87.7) | 38 (12.5) | 46 (12.4) | |
| ≥ 11.6 g/dL | 8 (12.3) | 267 (87.5) | 324 (87.6) | |
| Iron (mg/dL) | 80.1 ± 22.1 (32 - 111) | 72.9 ± 21.6 (18 - 120) | 74.1 ± 21.8 (18 - 120) | 74.1 ± 21.8 (18 - 120) |
| Calcium (mg/dL) | 10.1 ± 0.6 (8.8 - 10.8) | 10.1 ± 0.5 (7.4 - 10.6) | 10.1 ± 0.5 (7.4 - 10.8) | 10.1 ± 0.5 (7.4 - 10.8) |
| Calcium categorized | 0.005 b, c | |||
| < 8.8 mg/dL | 6 (9.2) | 5 (1.6) | 11 (3.0) | |
| ≥ 8.9 mg/dL | 59 (90.8) | 300 (98.4) | 359 (97.0) | |
| Phosphorus (mg/dL) | 4.9 ± 0.3 (4.5 - 5.5) | 4.6 ± 0.6 (3.3 - 5.9) | 4.9 ± 0.5 (3.3 - 5.9) | 0.006 c, e |
| Fasting blood sugar (mg/dL) | 83.6 ± 8.6 (68 - 104) | 86.1 ± 9.0 (65 - 115) | 85.7 ± 9.0 (65 - 115) | 0.039 c, e |
| Urea (mg/dL) | 19.8 ± 5.0 (13 - 29) | 23.0 ± 5.1 (15 - 38) | 22.4 ± 5.2 (13 - 38) | 0.150 d |
| Creatinine (mg/dL) | 0.59 ± 0.09 (0.5 - 0.9) | 0.6 ± 0.09 (0.5 - 0.9) | 0.6 ± 0.09 (0.5 - 0.9) | < 0.001 c, d |
| Uric acid (mg/dL) | 3.7 ± 0.5 (2.9 - 4.6) | 3.6 ± 1.1 (1.9 - 6.6) | 3.6 ± 0.99 (1.9 - 6.6) | < 0.001 c, d |
| Cholesterol (mg/dL) | 159.3 ± 27.8 (112 - 198) | 153.0± 24.2 (104 - 216) | 154.1 ± 24.8 (104 - 216) | 0.091 e |
| Triglyceride (mg/dL) | 76.1± 33.7 (25 - 171) | 84.5 ± 44.2 (29 - 216) | 83.0 ± 42.5 (25 - 210) | 0.023 c, d |
| Level of education, grade | 0.004 c, f | |||
| First | 20 (30.8) | 37 (12.1) | 57 (15.4) | |
| Second | 11 (16.9) | 79 (25.9) | 90 (24.3) | |
| Third | 14 (21.5) | 55 (18.2) | 69 (18.6) | |
| Fourth | 9 (13.8) | 43 (14.1) | 52 (14.1) | |
| Fifth | 6 (9.2) | 53 (17.4) | 59 (15.9) | |
| Sixth | 5 (7.7) | 38 (12.5) | 43 (11.6) |
Abbreviation: PBMCs, peripheral blood mononuclear cells
a All the continuous data were represented by the mean ± SD (for normally distributed data) or by the median and interquartile (for non-normally distributed data). Categorical data were presented by the No. (%).
b Fisher exact test
c Statistically significant
d Mann - Whitney U test
et-test
f Chi-square
| No. | Age/Gender | Nationality | ALT (IU/L) | AST (IU/L) | HCV-Ab | HCV-RNA in Plasma | HCV-Gen in Plasma | HCV-RNA in PBMCs | HCV-gen in PBMCs | HBs-Ag | HBs-Ab | HBc-Ab | HBe-Ag | HBe-Ab | HBV-DNA in Plasma | HBV-DNA in PBMCs | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113 | 12/M | Afghan | 19 | 20 | - | - | - | - | - | + | + | + | - | - | - | - | - |
| 122 | 11/F | Afghan | 17 | 18 | - | - | - | - | - | - | + | + | - | - | - | - | - |
| 166 | 10/M | Afghan | 23 | 25 | - | - | - | - | - | + | - | - | - | - | - | - | - |
| 177 | 12/M | Iranian | 15 | 14 | - | - | - | - | - | - | - | + | - | - | - | - | Isolated HBcAb |
| 283 | 15/M | Afghan | 27 | 30 | - | - | - | + | 1a | - | - | - | - | - | - | - | OCI |
Abbreviations: M, Male; F, Female; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; gen, Genotype; PBMCs, peripheral blood mononuclear cells; OCI, occult HCV infection

